Abstract
Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Volume: 16 Issue: 2
Author(s): Gholamreza Azizi, Hassan Abolhassani, Mohammad Hosein Asgardoon, Javad Rahnavard, Majid Zaki dizaji, Reza Yazdani, Javad Mohammadi and Asghar Aghamohammadi
Affiliation:
Keywords: Immunoglobulin, infection, primary antibody deficiency, primary immunodeficiency diseases.
Abstract: Immunoglobulin therapy represents a lifesaving intervention for many patients with primary immunodeficiency (PID). Antibody defects represent approximately half of the well-known PIDs requiring immunoglobulin replacement therapy. Following immunoglobulin therapy in PID patients, protection against serious upper and lower respiratory tract infections and pulmonary function improves which leads to an increase in the quality of life of these patients. Successful treatment of PID patients depends on the type of immunodeficiency, regular monitoring of the patient, comorbidities of the patient, and the availability of the products.
Export Options
About this article
Cite this article as:
Azizi Gholamreza, Abolhassani Hassan, Asgardoon Hosein Mohammad, Rahnavard Javad, dizaji Zaki Majid, Yazdani Reza, Mohammadi Javad and Aghamohammadi Asghar, The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (2) . https://dx.doi.org/10.2174/1871530316666160724214418
DOI https://dx.doi.org/10.2174/1871530316666160724214418 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Remifentanil with or without Propofol as Anesthesia Agents for Trans- Vaginal Ultrasonography Oocyte Retrieval (TUGOR) on Pregnancy and Anesthesia Outcomes: A Randomized Controlled Trial
Current Reviews in Clinical and Experimental Pharmacology The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications
Current Medicinal Chemistry The Inflammatory Response in Cardiac Surgery: An Overview of the Pathophysiology and Clinical Implications
Inflammation & Allergy - Drug Targets (Discontinued) Multicomponent Synthesis of New Generation of Arylindolylmethyl-1,3- Indandiones Using bis Ionic Liquid [BDBDIm]Br
Letters in Organic Chemistry Respiratory Burns: A Clinical Review
Current Respiratory Medicine Reviews Interaction of Drug or Food with Drug Transporters in Intestine and Liver
Current Drug Metabolism Microdialysis in Drug Discovery
Current Drug Discovery Technologies Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Hydrolases in Organic Chemistry. Recent Achievements in the Synthesis of Pharmaceuticals
Current Organic Chemistry Pharmacological Strategies for Neuroprotection in Traumatic Brain Injury
Mini-Reviews in Medicinal Chemistry Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression
Current Drug Targets Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design